

TDMs No. 20310 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 07/22/2009

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AZT)

Time Report Requested: 11:50:52

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C Number: C20310C

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 612 Vehicle 6 mo M Include 615 AZT 120 6 mo M

Study Gender: Male

TDMSE Version: 2.1.0

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Time Report Requested: 11:50:52

First Dose M/F: 11/18/04 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
---------------------------------------	----------------	----------------

Disposition Summary

Animals Initially in Study	27	26
Early Deaths		
Moribund Sacrifice		3
Survivors		
Moribund Sacrifice		1
Natural Death		1
Terminal Sacrifice	27	21
Animals Examined Microscopically	27	26

ALIMENTARY SYSTEM

Gallbladder	(26)	(26)
Intestine Large, Cecum	(27)	(26)
Hyperplasia, Lymphoid	3 [1.3]	1 [2.0]
Intestine Small, Jejunum	(27)	(26)
Liver	(27)	(26)
Fatty Change		1
Vacuolization Cytoplasmic	8 [1.1]	4 [1.0]
Pancreas	(27)	(26)
Salivary Glands	(27)	(26)
Infiltration Cellular, Lymphocyte	5 [1.0]	
Stomach, Glandular	(27)	(26)

CARDIOVASCULAR SYSTEM

Blood Vessel	(26)	(25)
Heart	(27)	(26)
Cardiomyopathy	2 [1.0]	

ENDOCRINE SYSTEM

Adrenal Cortex	(27)	(26)
Subcapsular, Hyperplasia	2 [1.0]	2 [1.0]
Thyroid Gland	(26)	(26)
Cyst		1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:50:52

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
Infiltration Cellular, Lymphocyte		1 [1.0]
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Epididymis	(27)	(26)
Preputial Gland	(27)	(26)
Atrophy		1 [3.0]
Prostate	(27)	(26)
Inflammation, Suppurative		1 [3.0]
Seminal Vesicle	(27)	(26)
Lumen, Dilatation		1 [1.0]
Testes	(27)	(26)
Seminiferous Tubule, Degeneration		1 [1.0]
HEMATOPOIETIC SYSTEM		
Bone Marrow	(27)	(26)
Myeloid Cell, Hyperplasia		1 [3.0]
Lymph Node	(0)	(1)
Lymph Node, Mandibular	(26)	(26)
Hyperplasia, Lymphoid	1 [1.0]	1 [1.0]
Lymph Node, Mesenteric	(27)	(25)
Hyperplasia, Lymphoid	19 [1.9]	16 [1.4]
Hyperplasia, Plasma Cell	1 [3.0]	
Spleen	(27)	(26)
Hematopoietic Cell Proliferation	1 [2.0]	2 [2.5]
Hyperplasia, Lymphoid	2 [2.0]	
Thymus	(26)	(26)
Atrophy		1 [4.0]
Hyperplasia, Lymphoid		2 [2.0]
INTEGUMENTARY SYSTEM		
None		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:50:52

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
MUSCULOSKELETAL SYSTEM		
Bone, Femur	(27)	(26)
NERVOUS SYSTEM		
Brain, Brain Stem	(27)	(26)
Brain, Cerebellum	(27)	(26)
Brain, Cerebrum	(27)	(26)
RESPIRATORY SYSTEM		
Lung	(27)	(26)
Abscess		1 [4.0]
Nose	(27)	(26)
Inflammation, Suppurative	1 [1.0]	1 [2.0]
SPECIAL SENSES SYSTEM		
Eye	(27)	(26)
Harderian Gland	(27)	(26)
Epithelium, Hyperplasia		1 [2.0]
URINARY SYSTEM		
Kidney	(27)	(26)
Bacterium		1 [2.0]
Infiltration Cellular, Lymphocyte	7 [1.0]	2 [1.0]
Inflammation, Chronic Active		1 [2.0]
Nephropathy		1 [4.0]
Pelvis, Dilatation		2 [2.0]
Transitional Epithelium, Hyperplasia	1 [1.0]	1 [2.0]
Urinary Bladder	(27)	(26)
Lumen, Dilatation	1 [3.0]	2 [2.5]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 20310 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]
3'-Azido-3'-deoxythymidine (AZT)
CAS Number: 30516-87-1**

Date Report Requested: 07/22/2009

Test Type: 26-39 WEEKS

Time Report Requested: 11:50:52

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

Vehicle 6 mo M

AZT 120 6 mo M

*** END OF MALE ***

*** END OF REPORT ***